Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis

被引：0
|
作者：
Mishriky, Basem M.
Tanenberg, Robert J.
Cummings, Doyle M.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
973-P
引用
收藏
页码：A252 / A252
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Niu, Yan-Li
    Zhang, Ye
    Song, Zhi-Yong
    Zhao, Chuan-Zhi
    Luo, Yun
    Wang, Yan
    Yuan, Jing
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (02) : 313 - 322
  • [2] SAFETY AND EFFICACY OF INSULIN GLARGINE/LIXISENATIDE AND INSULIN DEGLUDEC/INSULIN ASPART IN TYPE 2 DIABETES PATIENTS NOT CONTROLLED ON BASAL INSULIN: A NETWORK META-ANALYSIS
    Jammah, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A185 - A186
  • [3] Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
    Moon, Shinje
    Chung, Hye-Soo
    Kim, Yoon-Jung
    Yu, Jae-Myung
    Jeong, Woo-Ju
    Park, Jiwon
    Oh, Chang-Myung
    METABOLITES, 2021, 11 (09)
  • [4] Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis
    Edina, Brenda C.
    Tandaju, Jeremy R.
    Wiyono, Lowilius
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [5] Efficacy and safety of insulin degludec/insulin aspart vs biphasic insulin aspart 30: an international randomised trial in adults with type 2 diabetes fasting during Ramadan
    Hassanin, M.
    Echtay, A.
    Malek, R.
    Omar, M.
    Shaikh, S.
    Fita, E. G.
    Kaplan, K.
    Kamaruddin, N.
    DIABETOLOGIA, 2017, 60 : S75 - S75
  • [6] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
    Jammah, Anwar Ali
    PRIMARY CARE DIABETES, 2021, 15 (01) : 132 - 137
  • [7] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [8] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne Moeller
    Pan, Lili
    Liu, Weihong
    Zhao Weigang
    DIABETES, 2018, 67
  • [9] The Efficacy and Safety of Insulin Aspart 30 plus Metformin vs. Insulin Aspart 30 Alone in Treatment for Subjects with Type 2 Diabetes: A Randomized Controlled Trial
    Guo, Lixin, Sr.
    Chen, Li
    Chang, Bao Cheng
    Yang, Li Yong
    Liu, Yu
    Feng, Bo
    DIABETES, 2017, 66 : A255 - A255
  • [10] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
12345